PRA Health Sciences Company Profile

Background

PRA Health Sciences was a leading global contract research organization (CRO) headquartered in Raleigh, North Carolina. Established in 1976 as the Anti-Inflammatory Drug Study Group, the company expanded its services beyond inflammation research and was renamed PRA in 1982. Over the years, PRA grew significantly through strategic acquisitions, including the purchase of Symphony Health in 2017, which enhanced its data analytics capabilities. In July 2021, PRA was acquired by ICON plc, a global provider of outsourced drug and device development services, creating a combined entity with a broader service offering and geographic footprint.

Key Strategic Focus

PRA Health Sciences specialized in providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. Its strategic focus encompassed:

Clinical Development Services: Managing clinical trials across all phases, from early development to post-approval studies.

Data Solutions: Offering data management, statistical analysis, and real-world insights to support drug development processes.

Global Reach: Operating in over 90 countries, enabling the management of large-scale, multinational clinical trials.

Technological Integration: Incorporating advanced technologies, such as mobile and connected health platforms, to enhance trial efficiency and patient engagement.

Financials and Funding

PRA Health Sciences was a publicly traded company on NASDAQ under the ticker symbol PRAH. In 2017, the company reported revenues of approximately $2.87 billion. In 2019, PRA acquired Symphony Health for $530 million, expanding its data analytics capabilities. In February 2021, ICON plc announced an agreement to acquire PRA for approximately $12 billion, combining cash and stock considerations.

Pipeline Development

PRA Health Sciences was involved in numerous clinical trials across various therapeutic areas, including oncology, immunology, infectious diseases, neuroscience, and vaccines. The company participated in pivotal trials that led to the FDA and international regulatory approvals of over 85 products since 2000.

Technological Platform and Innovation

PRA Health Sciences utilized several proprietary technologies and scientific methodologies to enhance its clinical research capabilities:

Embedded Solutions™ Model: A pioneering approach that integrated PRA's resources with clients' teams to improve efficiency and flexibility in clinical development.

Mobile and Connected Health Platforms: Technologies designed to support decentralized and hybrid clinical trials, improving patient engagement and data collection.

Real-World Data and Analytics: Leveraging data from Symphony Health to provide insights into disease incidence, treatment patterns, and patient outcomes.

Leadership Team

Under the leadership of CEO Colin Shannon, PRA Health Sciences expanded its global presence and service offerings. Following the acquisition by ICON plc, Shannon continued to serve on the Board of Directors, contributing to the strategic direction of the combined entity.

Competitor Profile

PRA Health Sciences operated in a competitive landscape, contending with several major CROs:

ICON plc: A global provider of outsourced drug and device development services, headquartered in Dublin, Ireland.

IQVIA Holdings Inc.: A leading global provider of advanced analytics, technology solutions, and contract research services.

Labcorp Drug Development: A comprehensive drug development services company offering a broad range of solutions.

Parexel International Corporation: A global biopharmaceutical services organization providing comprehensive drug development and regulatory consulting services.

Syneos Health, Inc.: A biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO).

Strategic Collaborations and Partnerships

PRA Health Sciences engaged in several strategic collaborations to enhance its service offerings:

Symphony Health: Acquired in 2017, Symphony Health provided data analytics and technology solutions, strengthening PRA's data capabilities.

WuXi PharmaTech: In 2012, PRA formed a joint venture with WuXi PharmaTech to expand its clinical research services in China.

Operational Insights

PRA Health Sciences' global operations enabled it to manage large-scale, multinational clinical trials effectively. The company's Embedded Solutions™ model allowed for flexible and efficient integration with clients' teams, enhancing the overall clinical development process.

Strategic Opportunities and Future Directions

The acquisition by ICON plc in 2021 positioned the combined entity as a leader in healthcare intelligence and clinical research. The integration of PRA's capabilities with ICON's resources aimed to accelerate drug development processes, leveraging advanced technologies and a broader global presence to meet the evolving needs of the biopharmaceutical industry.

Contact Information

As of July 1, 2021, PRA Health Sciences became a wholly owned subsidiary of ICON plc. For information regarding the combined company's services and operations, please refer to ICON plc's official website.